Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury

Oncotarget. 2018 Oct 9;9(79):34857-34858. doi: 10.18632/oncotarget.26207.

Authors

Jonathan D Mizrahi¹, Michael J Overman¹

Affiliation

¹ Michael J. Overman: Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

No abstract available

Keywords: bevacizumab; hepatotoxicity; oxaliplatin; thrombocytopenia; vascular endothelial growth factor (VEGF).

Publication types

Editorial

Grants and funding

T32 CA009666/CA/NCI NIH HHS/United States